Spinal Cord Malignancy News

Friends holding benefit to help Totowa woman pay for cancer care - NorthJersey.com



NorthJersey.com
 
Friends holding benefit to help Totowa woman pay for cancer care 
NorthJersey.com
BY MATTHEW KADOSH TOTOWA - Less than 1 percent of people develop a malignant brain or spinal cord tumor, according to the American Cancer Society. Unfortunately, 44-year-old Wendy Bove is among that 1 percent. Wendy Bove, 44, has been fighting brain ...

 


New Medication to Reduce Bone Complications Now Available in Ontario - DigitalJournal.com (press release)



New Medication to Reduce Bone Complications Now Available in Ontario 
DigitalJournal.com (press release)
When cancer metastasizes to the bone, a number of serious complications can occur. These may include broken bones, spinal cord compression, as well as the need for radiation and/or surgery to the bone. In people with advanced prostate cancer, ...

and more » 


Fighting Brain Cancer: Taking out more than tumors - WFTV Orlando



Fighting Brain Cancer: Taking out more than tumors 
WFTV Orlando
BACKGROUND: Glioma is a broad term of brain and spinal cord tumors that comes from glial cells. Glial cells are the main brain cells that can develop into cancer. The symptoms, prognosis, and treatment of a malignant glioma can vary depending on the ...

 


Amgen Receives Complete Response Letter From FDA for XGEVAŽ sBLA for ... - MarketWatch (press release)



Amgen Receives Complete Response Letter From FDA for XGEVAŽ sBLA for ... 
MarketWatch (press release)
XGEVA has been approved in Mexico for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in patients with advanced malignancies involving bone. In Japan, Amgen is working ...

and more » 


QualityStocks News - European Medicines Agency Awards Arno Therapeutics AR-42 ... - Virtual-Strategy Magazine



QualityStocks News - European Medicines Agency Awards Arno Therapeutics AR-42 ... 
Virtual-Strategy Magazine
QualityStocks would like to highlight Arno Therapeutics, a publicly traded clinical-stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative ...

and more » 


Arno Therapeutics Announces Orphan-Drug Designation for AR-42 in Europe - SunHerald.com



Arno Therapeutics Announces Orphan-Drug Designation for AR-42 in Europe 
SunHerald.com
NF2 is a rare genetic disorder characterized by the growth of noncancerous tumors in the brain and spinal cord, juvenile cataracts and neurofibromas of the skin. The disease is caused by mutations in a gene which plays a role in preventing cells from ...

and more » 


Pet health: Are muscle spasms in dogs a sign of a more serious problem? - Newsolio (blog)



Newsolio (blog)
 
Pet health: Are muscle spasms in dogs a sign of a more serious problem? 
Newsolio (blog)
This toxin then prevents the release of inhibitory neurotransmitters in the brain and spinal cord, causing the muscles to spasm and contract until they become rigid. Tetanus often contracts the facial muscles and causes the jaw to become rigid (hence ...

 


Boy miraculously survives brain cancer - Covington News



Boy miraculously survives brain cancer 
Covington News
"It interferes with the cable system that carries all the information to the brain to the spinal cord and the information from the spinal cord up into the brain." Astrocytomas are nearly always deadly, because as they grow they interfere with more and ...

 


Brain Tumor Vaccine Shows Promise - Cancer Network



Brain Tumor Vaccine Shows Promise 
Cancer Network
Glioblastoma multiforme is the most prevalent type of primary malignant brain tumor. It is associated with a poor prognosis?the 5-year survival rate is approximately 4.5%. Overall, more than 22000 malignant brain and spinal cord tumors were diagnosed ...

and more » 


Arno gains orphan-drug status for AR-42 in Europe - Pharmaceutical Business Review



Arno gains orphan-drug status for AR-42 in Europe 
Pharmaceutical Business Review
AR-42 is currently being studied in a Phase I/IIa trial with relapsed or refractory hematologic malignancies patients and solid tumour patients. NF2 is a genetic disorder characterized by the growth of noncancerous tumours in the brain and spinal cord, ...

and more »